Literature DB >> 13204385

Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione).

B B BRODIE, T F YU, J J BURNS, T CHENKIN, B C PATON, J M STEELE, A B GUTMAN.   

Abstract

Entities:  

Keywords:  ANALGESICS

Mesh：

Substances：

Year:  1954        PMID： 13204385     DOI： 10.3181/00379727-86-21263

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


× No keyword cloud information.
  8 in total

1.  Evaluation of uricosuric agents in chronic gout.

Authors:  M A OGRYZLO; J HARRISON
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

2.  Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent.

Authors:  T F YU; B C PATON; T CHENKIN; J J BURNS; B B BRODIE; A B GUTMAN
Journal:  J Clin Invest       Date:  1956-04       Impact factor: 14.808

3.  Renal clearance of sulphinpyrazone in man.

Authors:  E G Lentjes; F G Russel; C A van Ginneken
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

Authors:  A K Pedersen; P Jakobsen; J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  Sulphinpyrazone metabolism during long-term therapy.

Authors:  A K Pedersen; P Jakobsen
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

6.  Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

Authors:  I D Bradbrook; V A John; P J Morrison; H J Rogers; R G Spector
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

7.  Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.

Authors:  F Schlicht; C Staiger; J de Vries; U Gundert-Remy; R Hildebrandt; J Harenberg; N S Wang; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.

Authors:  W A Ritschel
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.